BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

German mRNA company CureVac AG said founder and Chairman Ingmar Hoerr is replacing Daniel Menichella as CEO. Menichella joined the company as CBO as well as CEO of CureVac’s U.S. subsidiary in January 2017, becoming...
BioCentury | Oct 29, 2019
Politics & Policy

FDA’s Woodcock highlights gaps in knowledge about Chinese APIs, promotes advanced manufacturing to bolster U.S. security

A congressional hearing Wednesday on safeguarding pharmaceutical supply chains will focus on concerns that reliance on Chinese APIs threatens U.S. national security and creates health risks for American patients. The House Energy and Commerce Committee’s...
BioCentury | Dec 7, 2018
Company News

Management tracks: MiMedx, Akorn, Mallinckrodt

Following a spate of resignations this summer, MiMedx Group Inc. (NASDAQ:MDXG) announced three executive promotions. SVP of Strategic Initiatives Mark Landy was promoted to EVP and chief strategy officer. VP of Medical Affairs David Mason...
BioCentury | Jun 15, 2018
Clinical News

Flex downsizing on troubles with sole clinical program

Flex Pharma Inc. (NASDAQ:FLKS) said it is cutting headcount by about 60% after discovering its sole clinical program, FLX-787, will require additional work that stretch beyond the biotech's current means. Flex said it will evaluate...
BioCentury | Jun 13, 2018
Clinical News

Flex downsizing on troubles with sole clinical program

Flex Pharma Inc. (NASDAQ:FLKS) plummeted $3.14 (75%) to $1.04 on Wednesday when the company said it is cutting headcount by about 60% after discovering its sole clinical program, FLX-787, will require additional work that stretch...
BioCentury | Mar 17, 2015
Company News

Management tracks

Oral therapies developer Chiasma Inc. (Jerusalem, Israel) named Mark Leuchtenberger president and CEO. Leuchtenberger was president and CEO of Acusphere Inc. (Pink:ACUS). Leuchtenberger succeeds Roni Mamluk, whom Chiasma named chief development officer. mRNA technology company...
BioCentury | Feb 9, 2015
Finance

Royalty replay

With its first royalty fund fully deployed and returning cash, OrbiMed Advisors closed a second royalty fund that is 50% larger and recruited new LPs at research and healthcare institutions that could also help source...
BioCentury | Dec 18, 2014
Strategy

Translational balance

Different mindsets, motives and mandates have blocked the progress of companies and academics in forming deals to move discoveries from academia to industry. The solution is a balancing act that engages scientists in the partnerships,...
BioCentury | Sep 19, 2011
Company News

Acorda management update

Acorda Therapeutics Inc. (NASDAQ:ACOR), Hawthorne, N.Y. Business: Neurology, Musculoskeletal, Autoimmune Hired: Enrique Carrazana as CMO, formerly director of the epilepsy center of excellence at the Miami Veterans' Administration Hospital and an associate professor of neurology...
BioCentury | Nov 24, 2008
Finance

Ebb & Flow

A deal with Eli Lilly (NYSE:LLY) for exclusive U.S. rights to commercialize tadalafil for pulmonary arterial hypertension last week couldn't prevent United Therapeutics (NASDAQ:UTHR) from getting hosed after its oral treprostinil missed the primary endpoint...
Items per page:
1 - 10 of 125
BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

German mRNA company CureVac AG said founder and Chairman Ingmar Hoerr is replacing Daniel Menichella as CEO. Menichella joined the company as CBO as well as CEO of CureVac’s U.S. subsidiary in January 2017, becoming...
BioCentury | Oct 29, 2019
Politics & Policy

FDA’s Woodcock highlights gaps in knowledge about Chinese APIs, promotes advanced manufacturing to bolster U.S. security

A congressional hearing Wednesday on safeguarding pharmaceutical supply chains will focus on concerns that reliance on Chinese APIs threatens U.S. national security and creates health risks for American patients. The House Energy and Commerce Committee’s...
BioCentury | Dec 7, 2018
Company News

Management tracks: MiMedx, Akorn, Mallinckrodt

Following a spate of resignations this summer, MiMedx Group Inc. (NASDAQ:MDXG) announced three executive promotions. SVP of Strategic Initiatives Mark Landy was promoted to EVP and chief strategy officer. VP of Medical Affairs David Mason...
BioCentury | Jun 15, 2018
Clinical News

Flex downsizing on troubles with sole clinical program

Flex Pharma Inc. (NASDAQ:FLKS) said it is cutting headcount by about 60% after discovering its sole clinical program, FLX-787, will require additional work that stretch beyond the biotech's current means. Flex said it will evaluate...
BioCentury | Jun 13, 2018
Clinical News

Flex downsizing on troubles with sole clinical program

Flex Pharma Inc. (NASDAQ:FLKS) plummeted $3.14 (75%) to $1.04 on Wednesday when the company said it is cutting headcount by about 60% after discovering its sole clinical program, FLX-787, will require additional work that stretch...
BioCentury | Mar 17, 2015
Company News

Management tracks

Oral therapies developer Chiasma Inc. (Jerusalem, Israel) named Mark Leuchtenberger president and CEO. Leuchtenberger was president and CEO of Acusphere Inc. (Pink:ACUS). Leuchtenberger succeeds Roni Mamluk, whom Chiasma named chief development officer. mRNA technology company...
BioCentury | Feb 9, 2015
Finance

Royalty replay

With its first royalty fund fully deployed and returning cash, OrbiMed Advisors closed a second royalty fund that is 50% larger and recruited new LPs at research and healthcare institutions that could also help source...
BioCentury | Dec 18, 2014
Strategy

Translational balance

Different mindsets, motives and mandates have blocked the progress of companies and academics in forming deals to move discoveries from academia to industry. The solution is a balancing act that engages scientists in the partnerships,...
BioCentury | Sep 19, 2011
Company News

Acorda management update

Acorda Therapeutics Inc. (NASDAQ:ACOR), Hawthorne, N.Y. Business: Neurology, Musculoskeletal, Autoimmune Hired: Enrique Carrazana as CMO, formerly director of the epilepsy center of excellence at the Miami Veterans' Administration Hospital and an associate professor of neurology...
BioCentury | Nov 24, 2008
Finance

Ebb & Flow

A deal with Eli Lilly (NYSE:LLY) for exclusive U.S. rights to commercialize tadalafil for pulmonary arterial hypertension last week couldn't prevent United Therapeutics (NASDAQ:UTHR) from getting hosed after its oral treprostinil missed the primary endpoint...
Items per page:
1 - 10 of 125